Roche Doubles Down On SCLC By In-Licensing MediLink’s ADC

 
• By Dexter Jie Yan
  
lung cancer
MediLink's YL201 is currently being evaluated in a China-only Phase III clinical trial in ES-SCLC in a second-line setting. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business